# WEEK OF 2026-05-18 KAIZEN REVIEW

**Run date:** Sunday, 2026-05-24 ~21:30 ET (autonomous scheduled task — `weekly-sunday-kaizen`)
**Coverage window:** 2026-05-18 (Mon) → 2026-05-24 (Sun)
**Mode:** Weekly Sunday Kaizen — week-in-review + week-ahead + iteration
**Operator present:** No (scheduled, autonomous). Decisions made independently per task instructions.
**Compliance:** Amendments 027 (Real Data Only), 028 (Panel Integrity), 031 (Concentrated Regime), 032 (Hash Ledger), 033 (Cowork Dropbox), 034 (Daily Autoscan Persistence), 035 (Bulk V-ID Date Corrections), feedback_no_more_overrides_2026-05-19
**Authority:** /Odin Perfection/9REALMS_MASTER_LOG.md (3,660 lines, 338 KB), most recent entry 2026-05-22 Weekly Friday Pre-flight + Portfolio Lock + V-048 CRDF + Amendments 034/035 codification.

---

## 1. EXECUTIVE SUMMARY

This was a **first-loss week** for the Odin era plus a **portfolio lock + amendment ratification week**. The ALVO close on Tuesday 5/19 booked the Odin framework's first loss (-$1,624 realized) and triggered an immutable feedback directive prohibiting future overrides. By Friday 5/22 David locked the portfolio (UNCY $53,274 + CAPR $15,445 + CRDF $600 = $69,319 MV; +1.91% unrealized), opened V-047 CAPR and V-048 CRDF in the prediction-hash ledger, and three new amendments (033 Cowork Dropbox, 034 Daily Autoscan Persistence, 035 Bulk V-ID Date Corrections) were codified.

Three high-impact takeaways:

1. **ALVO -$1,624 loss = override violation**, not framework failure. Per `feedback_no_more_overrides_2026-05-19` memory: "yet again, please put the ALVO as an override of the program, that will be the last time." Every new entry must now score ≥4 stacked signals OR carry explicit override flag. **All 15 framework-driven wins, 1 override loss.** Honest win rate update: 15/16 = 93.75% (was 100% per Amendment 025).
2. **Portfolio LOCKED — no new entries until UNCY exits (~6/17).** UNCY is 76.9% of account (above the 50% Amendment 031 cap) but David has explicitly authorized this concentration. Phase B post-UNCY rotation opens 6/17+, Phase C post-CAPR opens 8/12+. Cash flow plan is documented in `PORTFOLIO_LOCKED_2026-05-22.md`.
3. **Three IMMUTABLE amendments shipped this week** — 033 (every Cowork scan must write to `/9realms/odin_cowork_dropbox/`), 034 (every scheduled scan must persist to `/Odin Perfection/DAILY_AUTOSCAN_REPORTS/`), 035 (bulk V-ID date corrections + IRON CNPV failure documented as first-ever post-CNPV CRL). Daily-scan mirror to `/9realms/daily_scans/` and ODIN_INBOX/ cross-chat publication chain remain in force.

**Realized P&L this week:** -$1,624 (ALVO, single trade closed 5/19).
**Cumulative Odin-era ledger (per Trade Ledger v3 2026-05-19):** 16 closed trades, 15 wins, 1 loss, win rate 93.75%, pool ROI +17.96%, total P&L +$53,635.63 on $298,705 cost basis, average return +33.0%, avg hold 14.5 days.
**Open positions:** UNCY 6,593.31 sh ($53,274 MV / $52,443 cost / +1.59%), CAPR 535 sh ($15,445 MV / $14,555 cost / +6.12%), CRDF 40 calls $2.50 6/18 ($600 MV / $1,026 cost / -41.52%).
**Cardinal Rule violations:** 0 in the week (ALVO loss was an entry-rule override, not a Cardinal Rule violation — Cardinal Rule = never hold through binary; ALVO closed pre-BLA).

---

## 2. WEEK-IN-REVIEW

### 2.1 Daily news scan signal-vs-noise (5/18 → 5/22)

| Day | HIGH alerts | What mattered | What was noise |
|-----|------------:|---------------|----------------|
| 5/18 (Mon) | 2 | UNCY date drift (calendar 6/27 vs CEO 6/29 — first flag); ACHV CRL pre-declared on/before 6/20 PDUFA + Q3'25 cGMP context | AVTX/TRDA/ALXO/AXSM already-fired noise |
| 5/19 (Tue) | 9 | UNCY date drift (2nd flag); MNKD label correction (Afrezza ped, not Tyvaso); IRON label correction (DISC-0974, not bitopertin); CADL/MIRM/AVTX already-fired cleanup; WVE first formal prediction closed (scientific A+, stock D — -5.47% sell-the-news) | AARD ARD-101 clinical hold (not on watchlist) |
| 5/20 (Wed) | 7 | TRDA -48/-57% data-good-market-bad anchor; CAPR insider forensics resolved → revised LEAN MILDLY BEARISH after Form 144 ID'd director Musket selling entire $2.4M position discretionarily 12d post-TRDA fail; MNKD T-7 (no position); ZBIO relabel | UNCY 6/27 vs 6/29 still unresolved (3rd day flagged) |
| 5/21 (Thu) | 6 | CRDF ASCO abstract #3510 released; IRON Abstract #6501 released (prior data); CAPR lawsuit + insider stack; UNCY date primary source = **6/29** (CEO direct quote authoritative) | MNKD competitor narrative is 12-week-old |
| 5/22 (Fri) | 4 | MNKD T-5 exit signal (no position); CRDF T-7 exit signal (40 calls salvage, exit window 5/26-6/1); **ACHV NEW MATERIAL FACT** — two Form 483 observations at named cytisinicline manufacturer in Q1 2026 8-K, BLOCK reinforced; UNCY date drift (4th day flagged); GANX (off-watchlist) Phase 1b update fired | NMRA KOASTAL-2/3 still pending |

**Net signal quality:** Calendar hygiene was again the highest-volume signal. UNCY date drift took 4 trading days to resolve (canonical CSV still not corrected as of Friday close). **ACHV CMC observation on 5/22 is the single most valuable new fact of the week** — it converts the ACHV BLOCK from "company-pre-announced CRL" to "company-pre-announced CRL + verifiable manufacturer Form 483 in same NDA" and is direct training data for the v15 CMC-risk feature (companion to `pw_double_crl_bin_x_resub_class_2 = -0.173`).

### 2.2 UW flow monitor signals (5/22 — most recent batch)

| Class | Count | Names | What it told us |
|-------|------:|-------|-----------------|
| RED | 6 | AVTX, MNKD, NMRA, TSHA, VRDN, WVE | Distribution signals — institutional rotation OUT. None in portfolio. **VRDN +DP 13.8x + put_ab jump 233x is the loudest signal** (large-cap launch-readiness skepticism for veligrotug pre-6/30 PDUFA); **WVE call-premium flip pos→neg confirms 5/19 sell-the-news rotation persisting**; **MNKD distribution into T-5 PDUFA validates Cardinal Rule exit (no position held)**. |
| YELLOW | 3 | AXSM, CABA, ZBIO | Flow weakening. CABA dark-pool drying up (-80% one day) ahead of EULAR 6/3-6/6 — could mean either pre-conference de-risking or hedge-unwind. Watch but no entry triggered. |
| GREEN | 7 | ACHV, ARQT, CRDF, IRON, TRDA, UNCY, VERA | **Most relevant to portfolio:** CRDF call_vol_z +1.10 + net_call $13K (smart money still positive into ASCO Jun 2); UNCY net_call positive on tiny volume; VERA still GREEN for July 7 PDUFA candidate. **ACHV GREEN is a contradictory signal** — flow says buying interest but Pre-Investment Discovery BLOCK overrides. |

**Live monitor still functional:** UW flow ingestion pipeline is producing daily reports (last batch 5/22). No 3-week staleness recurrence like the 5/8→5/17 gap that prior kaizen flagged.

### 2.3 Positions audit (real, ground truth)

| Position | Cost basis | MV (Fri 5/22 close) | Unrealized | Catalyst | Hard stop | Compliance |
|----------|-----------:|--------------------:|-----------:|----------|-----------|------------|
| UNCY 6,593.31 sh (ML 4,586 + TOS 2,007.31) | $52,442.53 | $53,273.95 | +$831 (+1.59%) | OLC PDUFA **2026-06-29** (Mon) | 2026-06-17 (Wed, T-7) | Cardinal Rule: pre-authorized exit window 6/12-6/17. 76.9% concentration acknowledged + David-locked. |
| CAPR 535 sh | $14,554.89 | $15,445.45 | +$891 (+6.12%) | Deramiocel PDUFA 2026-08-22 (Sat, effective Fri 8/21) | 2026-08-12 (Wed, T-7) | Cardinal Rule: pre-authorized. Insider Form 144 (Musket $2.4M discretionary) + lawsuit = re-rate BEARISH; Phase B/C tranches downsized. |
| CRDF 40 calls $2.50 6/18/26 | $1,026.00 | $600.00 | -$426 (-41.52%) | ASCO Rapid Oral Abstract #3510 2026-06-02 | **2026-06-01 (Mon, D-1)** | Salvage trade. Options expire AFTER catalyst — must sell IV premium D-1 regardless of value. |
| **Totals** | **$68,023.42** | **$69,319.40** | **+$1,295.98 (+1.91%)** | — | — | — |

**Closed this week (1):**

| Trade | Open date | Close date | Hold (days) | Cost | Proceeds | P&L | Override | Reason |
|-------|-----------|-----------|------------:|-----:|---------:|----:|----------|--------|
| ALVO | (pre-5/19) | 2026-05-19 | — | ~$25K | ~$23.4K | **-$1,624 (-6.5%)** | ⚠️ YES | Per David verbatim: "I felt like we'd have a bounce at the BLA and, we probably would have, but I can't wait around when CAPR is down from 34 to 27, the bigger opportunity is there." Closed to free capital for CAPR rotation. |

**Cardinal Rule compliance:** 0 violations this week. ALVO was closed BEFORE its binary event (entry was the override, not the exit). UNCY/CAPR/CRDF all have pre-authorized exits locked in well before binary dates.

### 2.4 Master log / kaizen log review (last 5 entries)

The KAIZEN_LOG.md most recent block adds 4 ITERATE candidates from the 5/22 weekly preflight:
- ODIN v15: `wve_sell_the_news_2026-05-19` (positive data + stock -5.47%)
- ODIN v15: `trda_data_market_divergence_2026-05-07` (data good / market bad)
- ODIN v15: `achv_cgmp_inspection_observations_2026Q1` (CMC-risk training datum)
- CONF v1.1: `pres_type_rapid_oral` (between Poster +4% and Oral +8%, ~+5-6%)

All four candidates are queued for the next ODIN v15 / CONF v1.1 training cycle. None of them ship without panel-level validation per Amendment 028. Trajectory: the framework's improvement vector this week was operational (publication chain + persistence + portfolio lock + first-loss-acceptance), not statistical (no model retrain).

---

## 3. WEEK-AHEAD (2026-05-25 → 2026-05-31)

### 3.1 All catalysts landing next 7 days (from `UNIFIED_FORWARD_CATALYST_UNIVERSE_2026-05-22.json`)

**Monday 5/25 is Memorial Day — markets closed. Trading week is Tue 5/26 - Fri 5/29 (4 days) + Sun 5/31 PDUFA dates effectively Mon 6/1.**

40 catalysts in window. ASCO 2026 dominates (May 29 - Jun 2; abstracts release rolling). Key items by class:

#### A. PDUFA dates (3 — Tier A, firm)

| Ticker | Date | Drug | Indication | Position? | Action |
|--------|------|------|------------|-----------|--------|
| **MNKD** | 2026-05-29 (Fri) | Afrezza pediatric sBLA | T1D/T2D ped | NO | Watch only. T-5 exit triggered 5/22 — no position to manage. UW flow RED into PDUFA. |
| **CING** | 2026-05-31 (Sun, effective Mon 6/1) | Centanafadine | ADHD | NO | **NEW T-21 item.** Pre-Investment Discovery BLOCK (CMC + CRL history per memory). DO NOT ENTER regardless of any model tier upgrade. |
| **LTRN** | 2026-05-31 (Sun, "Regulatory Decision") | LP-300 + carbo/pem | NSCLC | NO | Nano-cap ($34M). "Regulatory Decision" classification suspect — needs Rule 0 verification before any tier consideration. Likely not a true PDUFA. |

#### B. Topline data readouts (2)

| Ticker | Date | Drug/Trial | Indication | Position? | Action |
|--------|------|------------|------------|-----------|--------|
| **ALT** | 2026-05-28 (Thu) | Pemvidutide | MASH Phase 2b | NO | Small-cap ($545M). Real binary; would qualify for framework consideration in normal regime. **Amendment 031 portfolio lock = NO new entries.** Watch + log outcome for v15 calibration. |
| **NTHI** | 2026-05-31 (Sun) | NeoTX brain cancer Phase 2 | IDH1 Astrocytoma | NO | Micro-cap ($139M). Same — watch, do not enter. |

#### C. Conference presentations — ASCO 2026 starts 5/29 (35+ items in window)

Highest-relevance ASCO items in framework universe (multi-program, T-1 verified):

| Ticker | Date | Type | Indication | Position? | Action |
|--------|------|------|------------|-----------|--------|
| **IDYA** | 2026-05-29 | Conf (Phase 2/3) | 1L HLA-A*02-neg mUM | NO | Mid-cap, already-reported Apr 13 lead-in. Watch for ASCO data quality. |
| **CMPX** | 2026-05-29 | Conf (Phase 1) | Solid tumors | NO | Was the framework's $-77% retail-era loss — flow profile is RED-prone. Watch only. |
| **CRDF** (locked position) | 2026-06-02 (Tue, Rapid Oral) | Conf (Phase 2) | 1L RAS-mut mCRC | YES (40 calls) | **Active exit window 5/26 → 6/1.** Pull abstract #3510 from ASCO.org first thing 5/26. If ORR/PFS ≥ Apr 2025 baseline (ORR 17.1% vs 5.3%), ride into Mon 6/1 close, then hard-exit. If materially weaker, scratch salvage Tue 5/26. |
| **IRON** | 2026-06-02 (Tue, Oral) | Conf (Phase 2) | RALLY-MF anemia of MF | NO | DISC-0974 abstract released 5/21 (prior data only). Pre-oral entry only if TI rate ≥40% (program-defining bar). No portfolio slot. |

#### D. Multi-program watchlist items (active monitoring, no new entry)

- **CABA** — EULAR 6/3-6/6 multi-presentation slate. Sept 4 INDIGO IgG4-RD complete data; SunStone SLE Q4 2026. Closed +$2,488 ASGCT pre-empt; no current position.
- **VERA** — July 7 PDUFA atacicept IgAN. Priority Review + BTD intact. Watch flow into June for entry-candidate qualification post-CAPR exit (8/12).
- **NMRA** — KOASTAL-2/3 joint topline Q2 2026, could drop any day through 6/30. **NO POSITION** per Rule 0 (Phase 3 retry after KOASTAL-1 fail = elevated binary failure prior).
- **VRDN** — June 30 PDUFA veligrotug TED. **UW flow RED 5/22 (DP spike 13.8x, put_ab jump 233x).** Watch but Amendment 031 lock prevents entry.

#### E. Chain integrity issue surfaced (5/24 autoscan)

The 5/24 auto-postmortem scan reported **23/25 ledger entries OK, 2 BAD** (entries #15 + #16 file-hash mismatch + chain break). This must be investigated as the first action of Tuesday 5/26 session. Likely cause: file rewrites on entries #15 or #16 after hashing. If hashes can't be reconciled to source files, a chain rebuild is required per Amendment 032 immutability protocol.

### 3.2 Top 3-5 actions for the week (David priorities)

1. **TUESDAY 5/26 PRE-OPEN: pull CRDF ASCO Abstract #3510 from ASCO.org.** Read data independently. Apr 2025 baseline = ORR 17.1% (onv+SoC+bev) vs 5.3% (paclitaxel control). If at-or-above baseline, hold calls into Mon 6/1 close. If materially weaker, scratch the salvage immediately Tue open. Calls expire 6/18 = AFTER catalyst; IV premium evaporates at the event regardless of stock direction.
2. **TUESDAY 5/26: investigate ledger chain integrity failure** (entries #15 #16 BAD per 5/24 autoscan). Either reconcile file hashes to current source state or run a chain rebuild and document the version change per Amendment 035 version-field protocol.
3. **WEDNESDAY 5/27: update canonical calendar UNCY 6/27 → 6/29.** This is now a 5-trading-day flagged item. Once corrected, recompute UNCY exit triggers (T-5 = Tue 6/23 if T-5 trading; T-7 = Wed 6/17 stays as the BIFROST hard stop).
4. **DAILY THROUGH FRI 5/29: monitor MNKD PDUFA outcome.** Not in portfolio but the outcome is a v15 calibration datapoint — Afrezza pediatric sBLA is the year's best-clean small-cap PDUFA test of the framework's 2025+ retail-era "approvals come early or on-date, never late" rule (Amendment 011 sibling). Log T-0 silence / approval timing for the dashboard.
5. **WED-THU 5/27-5/28: verify CAPR AdCom status directly at fda.gov/advisory-committees.** This is the 3rd day open. Class II resub for cell therapy is AdCom-eligible. If no AdCom announced by EOW, treat the AdCom risk as "absence of evidence, not evidence of absence" but downsize CAPR Phase B (no upsize) — current 535 sh equity stays.

### 3.3 New T-21 candidates (5/25 - 6/14, nano/micro/small)

52 catalysts in the T-21 window. **Per Amendment 031, the portfolio is LOCKED until UNCY exits (~6/17).** No new entries permitted regardless of model tier. The following are surfaced for post-6/17 Phase B re-screening:

**Tier A PDUFA (firm-date binary):**
- **ARVN 2026-06-05** — Breast cancer PROTAC, small ($646M). **Note: ARVN VEPPANU already approved 5/1** — this 6/5 entry likely refers to a different ARV-* asset or is a stale calendar entry. **Must Rule 0 verify before consideration.**
- **CING 2026-05-31** — Pre-Investment Discovery BLOCK (no entry).
- **MNKD 2026-05-29** — already managed (no position).

**Tier B real binary (topline data, conference orals with new data):**
- **ALT 2026-05-28** — Pemvidutide Phase 2b MASH topline, small ($545M). Real binary. Watch outcome for v15 calibration; **post-6/17 candidate if pre-Aug catalyst still alive**.
- **CRDF 2026-06-02** — managed.
- **IRON 2026-06-02** — watch outcome for v15 calibration.
- **HUMA 2026-06-11** — Phase 3 hemodialysis topline, micro ($199M). Real binary, **likely Phase B candidate post-UNCY exit**.

**Watchlist additions for Phase B/C screening (post-6/17 and post-8/12):**
- NUVL Sep 18 PDUFA zidesamtinib ROS1+ NSCLC (small, BTD + Orphan)
- MLYS Dec 22 PDUFA (small)
- COGT Dec 30 PDUFA + 5/30 ASCO Phase 3 GIST (mid)
- DYN, WVE, RNA, IMVT, CNTA, TRDA, EWTX, ABVX (per Rocket Finder v1.0 top 10)

**Out-of-scope by design (per `feedback_no_preclinical_nanocap_rockets_2026-05-22`):** all ASCO conference presentations from nano-cap (<$50M) preclinical/Phase 1 programs (APRE $10M, GNPX $9M, MTVA $6M, BCDA $10M, etc.). David verbatim: "nah, good to knwo what happened, but we won't chase these things." Will NOT propose entries on any AKTX-class setup (preclinical + nano + PIPE).

---

## 4. KAIZEN ITERATION

### 4.1 ALVO postmortem (the only closed trade)

**Setup:** ALVO entry as a contrarian pre-BLA bounce play. Held through Mon 5/18 deepening drawdown.

**Outcome:** -$1,624 realized 2026-05-19. CAPR rotation justified the exit (CAPR was $34 → $27 the same window, opportunity cost dominated).

**Root cause:** Entry was **not** a framework signal — it was a David override on conviction ("I felt like we'd have a bounce at the BLA"). The framework score was below the 4-stack threshold; ALVO would not have entered through `position_optimizer_v1.py` gates.

**Lesson codified:** `feedback_no_more_overrides_2026-05-19.md` — every new entry MUST (a) score Tier 1 or Tier 2 stacked ≥4 in current ledger, (b) have SHA-256 hashed prediction per Amendment 032, (c) specify catalyst type explicitly per `feedback_catalyst_type_clarity`, (d) have specialist signal pass, (e) size per Amendment 031. If a non-framework entry is proposed, the response is: *"⚠️ This trade does not satisfy framework criteria. Per feedback_no_more_overrides_2026-05-19, we committed no more overrides. NO ENTRY default. Explicit override requires 'Override the no-overrides directive because {reason}' + ⚠️ OVERRIDE flag on the ledger."* Cumulative lifetime override damage estimated at ~-$60K to -$85K — ALVO is in that lineage.

**Honest win-rate update:** 15 wins / 1 loss / 16 trades = **93.75%** (was 100% in Amendment 025). Pool ROI +17.96% over the Odin era. **Pre-override-loss-streak monitor activated** — if a second override loss happens, the rule sharpens to NO_OVERRIDES_EVER.

### 4.2 Pattern analysis this week

1. **Sell-the-news pattern is repeating in 2026.** WVE delivered scientifically-validated positive data 5/18 (Z-AAT -71%, MZ phenotype both BiW + monthly), stock down -5.47% on 5/19. Combined with TRDA's data-good/market-bad (Cohort 1 met safety/tolerability, market sold -48 to -57% on PK shortfall narrative). **Two anchors this week alone.** v15 candidate feature `post_readout_sell_news_d1_pct_negative_given_positive_outcome` is now backed by two distinct anchors — graduate from ITERATE to a SHIP-CANDIDATE after one more anchor or after panel-level validation on 2025+ Phase 1/2/2b readouts.

2. **ACHV CMC observation = textbook v15 training datum.** The Form 483 observations on the named cytisinicline manufacturer 5-7 weeks pre-PDUFA, disclosed in Q1 2026 8-K, combined with the company-pre-announced CRL (Apr 15 PR), are a clean labeled positive case for the v15 CMC-risk feature `pw_double_crl_bin_x_resub_class_2` (current coef -0.173 in v14). Add to training set tagged `achv_cgmp_inspection_observations_2026Q1` with outcome label pending 6/20 PDUFA. **Pre-Investment Discovery BLOCK on ACHV is REINFORCED.**

3. **Conference acceptance — Rapid Oral as a distinct tier.** ASCO 2026 surfaced two rapid oral abstracts on framework names (CRDF Abstract #3510 + IRON Abstract #6501). CRDF moved up the Conference Overlay scoring vs poster baseline. v1.1 candidate `pres_type_rapid_oral` should be interpolated between Poster (+4%) and Oral (+8%), suggested +5-6%. Backtest is needed against the 2025-2026 ASCO/ASH/AACR cohort — `conference_trades_apr_may_2026.json` already has 21 anchors that can extend the dataset.

4. **NCCN amplifier signal opportunity** (per memory `nccn_amplifier_signal_2026-05-22`). NCCN pre-approval Category 2A inclusion = positive amplifier for oncology V-IDs (n=5 confirmed cases: IBRX, Ferring/ADSTILADRIN, SNDX Revumenib NPM1m AML 9/2025, SNDX KMT2A, KURA Ziftomenib 11/2025). Two-channel overlay design: (a) positive amplifier (Cat 1 +20%, Cat 2A +15%, Cat 2B +8%), (b) competitor-crowding penalty (drug absent / competitor present in NCCN = -8%). **Current portfolio impact:** NUVL gets -8% (taletrectinib ROS1 NSCLC already NCCN Cat 2A); COGT gets -8% (Ayvakit + Rydapt already NCCN); UNCY/CAPR/CRDF non-oncology = N/A. Build NCCN scraper + FMP 8-K filter for inclusion-announcement PRs. Ship as overlay v1.0 with "underpowered backtest" caveat (n=5). Companion to Smart Money + Conference + UOA overlays.

5. **Smart Money signal correlation check.** This week:
   - CAPR (locked position, +6.12%): Insider Form 144 ($2.4M discretionary, director Musket entire liquidation) = NEGATIVE smart money. Stock rose on relief from CRL-lifted Phase III BLA-resub timeline confirmation, NOT due to smart money. **Smart Money signal correctly flagged bearish; price went the other way for unrelated reasons.** This is a single counter-example; full v1.0 validation still pending.
   - UNCY (locked position, +1.59%): No insider activity flagged; smart money signal NEUTRAL. Price action neutral. **CONSISTENT.**
   - CRDF (locked salvage, -41.52% MTM): UW flow GREEN 5/22 (net call $13K, +1.10 z-score). Smart money signal POSITIVE; price flat/up Friday close. **CONSISTENT.**
   - ALVO (closed -$1,624): No formal smart money read taken at entry — would have failed the 4-stack gate. **Confirms override-loss attribution to gate-bypass, not signal failure.**

### 4.3 Mini-postmortems for closed trades (1 this week)

**ALVO 2026-05-19** — already postmortem'd in section 4.1. One-line ledger entry queued for `KAIZEN_LOG.md` append:

```
| 2026-05-19 | META | override-loss | ALVO -$1,624 first Odin-era loss = entry override violation. New rule: no entry without 4-stack OR explicit override flag. | -100% framework alpha attribution (loss is override-attributable) | -100% | n=1 | KILL_OVERRIDES | feedback_no_more_overrides_2026-05-19 | ODIN_TRADE_LEDGER_2026-05-19.json |
```

### 4.4 New edges worth testing (queued for next kaizen cycle)

1. `post_readout_sell_news_d1_pct_negative_given_positive_outcome` (v15 ODIN candidate; 2 anchors WVE + TRDA + maybe ATRA from history) — see 4.2.1
2. `pres_type_rapid_oral` (CONF v1.1 candidate; interpolate +5-6% between Poster and Oral) — see 4.2.3
3. `achv_cgmp_inspection_observations_2026Q1` (v15 CMC-risk training datum) — see 4.2.2
4. `data_market_divergence_post_readout` (binary feature: did stock reaction contradict clinical outcome direction?) — TRDA + WVE both qualify
5. `nccn_amplifier_signal` (overlay v1.0 with n=5 underpowered backtest caveat) — see 4.2.4
6. `t0_silence_detector` (sibling of T-3 silence detector; if PDUFA date passes with no 8-K by close, asymmetry breaks → flip bearish read) — original surface from kaizen_weekly_2026-05-17, still queued
7. **Chain integrity rebuild protocol** — if file hash mismatches happen (as on 5/24 autoscan for entries #15 #16), need a documented rebuild + version-bump procedure that preserves Amendment 032 immutability. Operational priority.

### 4.5 Cardinal Rule refinements

No Cardinal Rules need updating this week. The existing set survived a first-loss event correctly:
- ALVO was NOT a Cardinal Rule violation (closed pre-binary).
- ALVO WAS an entry-gate override violation — addressed by `feedback_no_more_overrides_2026-05-19`, a new feedback rule (not a Cardinal Rule change).
- UNCY/CAPR/CRDF all have pre-authorized exits ≥T-7. Compliant.
- The 76.9% UNCY concentration violates the Amendment 031 50% cap but David explicitly authorized this state ("make it immutable until I tell you to change them" — 5/22 16:00 ET). Logged + flagged, not a rule change.

### 4.6 Update to `CATALYST_DATE_VERIFICATION_PROTOCOL.md`?

**No change needed this week.** The protocol caught all four date-drift items in real time (UNCY 6/27 vs 6/29 — flagged 4 days running, primary source confirmed; MNKD Tyvaso vs Afrezza label correction; IRON bitopertin vs DISC-0974 label correction; AVBP "early 2026" → "mid-2026" guidance slip). The 4-day delay on the UNCY canonical CSV correction is an **operational** issue (no one has run the CSV edit), not a protocol failure. Recommend: add an auto-edit step to the daily scan task — if a date drift is flagged ≥3 days, the next scan auto-corrects the canonical CSV and surfaces a confirmation prompt.

---

## 5. SYSTEM DIRECTIVE UPDATES THIS WEEK

- **2026-05-19** — `feedback_no_more_overrides_2026-05-19` (HARD FEEDBACK DIRECTIVE) — committed after ALVO loss
- **2026-05-21** — Amendment 033 IMMUTABLE — Cowork Dropbox (every Cowork scan writes to `/9realms/odin_cowork_dropbox/`)
- **2026-05-22** — Amendment 034 IMMUTABLE — Daily Autoscan Persistence (every scheduled scan persists to `/Odin Perfection/DAILY_AUTOSCAN_REPORTS/`)
- **2026-05-22** — Daily Scan Mirror IMMUTABLE — every daily catalyst news scan mirrors to `/9realms/daily_scans/` (byte-identical)
- **2026-05-22** — Amendment 035 IMMUTABLE (renumbered from collision with 034) — Bulk V-ID Date Corrections; **IRON CNPV failure documented as first-ever post-CNPV CRL** (CNPV booster stripped from IRON model adjustments)
- **2026-05-22** — Portfolio LOCKED (immutable until David clears)
- **2026-05-22** — V-047 CAPR opened; V-048 CRDF opened
- **2026-05-21** — Catalyst Type Clarity feedback (every entry leads with "Catalyst type: [TYPE] — [event] on [date]. Binary risk: HIGH/MED/LOW.")

---

## 6. PUBLICATION CHAIN COMPLIANCE AUDIT

Per Amendment 029 (Cross-Chat Publication), this kaizen MUST be cross-published. Per Amendments 033 (Cowork Dropbox), 034 (Daily Autoscan Persistence), and the Daily Scan Mirror, mirroring is mandatory:

| Path | Purpose | Compliance |
|------|---------|------------|
| `/Odin Perfection/kaizen_weekly_2026-05-24.md` | Primary canonical | ✓ Written |
| `/Odin Perfection/DAILY_AUTOSCAN_REPORTS/2026-05-24_weekly_kaizen_review.md` | Amendment 034 autoscan persistence | ✓ Mirrored |
| `/9realms/daily_scans/kaizen_weekly_2026-05-24.md` | Daily Scan Mirror (byte-identical) | ✓ Mirrored |
| `/9realms/odin_cowork_dropbox/2026-05-24_weekly_kaizen_review.md` | Amendment 033 Cowork Dropbox | ✓ Mirrored |
| `/9realms/ODIN_INBOX/2026-05-24/kaizen_weekly_2026-05-24.md` | Amendment 029 Cross-Chat Publication | ✓ Mirrored |

---

## 7. NEXT-SESSION ACTION ITEMS (per Amendment 034)

1. **Tue 5/26 pre-open:** Pull CRDF ASCO Abstract #3510 + read independently. Execute Cardinal Rule exit decision on 40 calls.
2. **Tue 5/26:** Investigate ledger chain integrity failure (entries #15 #16 BAD per 5/24 autoscan).
3. **Tue 5/26:** Verify CAPR AdCom status directly via fda.gov/advisory-committees (3rd day open).
4. **Wed 5/27:** Update canonical CSV UNCY 6/27 → 6/29 (5th day flagged).
5. **Fri 5/29 close:** Log MNKD PDUFA outcome (no position) as v15 calibration datum.
6. **End of next week:** Build `pres_type_rapid_oral` backtest using existing `conference_trades_apr_may_2026.json` + 2025-2026 ASCO/ASH/AACR cohort.
7. **End of next week:** Draft NCCN amplifier v1.0 overlay spec + scraper architecture.

---

## 8. COMPLIANCE ATTESTATION

- **Amendment 027 (Real Data Only):** ✓ Output separates VERIFIED / INFERRED / UNRESOLVED / RED-TEAM. All position values from PORTFOLIO_LOCKED_2026-05-22.md (primary source). All catalyst dates from primary IR / SEC sources logged in daily scans. ⚠️ DATA NOT VERIFIED flags: CING 5/31 is a Sunday — effective PDUFA likely 6/1 (needs Rule 0 verification); ARVN 6/05 entry needs Rule 0 verification (different asset from already-approved VEPPANU).
- **Amendment 028 (Panel Integrity):** ✓ No new panel-conditional rates computed this kaizen. All numbers attributed to specific source files.
- **Amendment 031 (Concentrated Regime):** ✓ Portfolio audit completed. UNCY 76.9% over 50% cap = explicit David-locked deviation. CAPR 22.3% in band. CRDF 0.9% below 10% min = salvage exception.
- **Amendment 032 (Universal Prediction Hash):** ✓ No new V-IDs opened in this kaizen (V-047 CAPR + V-048 CRDF already in ledger from 5/22 entries). Chain head `a684e1d9b1e3b85d25944d7ce35cb713b7792bc16d67063cc1c11b8cc0b22691`. **⚠️ Chain integrity failure flagged for 5/26 investigation.**
- **Amendment 033 (Cowork Dropbox):** ✓ This file mirrored to `/9realms/odin_cowork_dropbox/2026-05-24_weekly_kaizen_review.md`.
- **Amendment 034 (Daily Autoscan Persistence):** ✓ This file mirrored to `/Odin Perfection/DAILY_AUTOSCAN_REPORTS/2026-05-24_weekly_kaizen_review.md`.
- **Daily Scan Mirror:** ✓ Mirrored to `/9realms/daily_scans/kaizen_weekly_2026-05-24.md`.
- **Cross-chat publication (Amendment 029):** ✓ Mirrored to `/9realms/ODIN_INBOX/2026-05-24/kaizen_weekly_2026-05-24.md`.
- **feedback_no_more_overrides_2026-05-19:** ✓ ALVO loss documented as override-attributable, not framework failure. New entry default = NO ENTRY unless 4-stack threshold met.

---

## 9. ONE-LINE WEEK VERDICT

**The framework took its first Odin-era loss this week (-$1,624 on ALVO, override-attributable), locked the portfolio, ratified three immutable amendments, committed to no-more-overrides, and exits the week with $69,319 MV / +1.91% unrealized on three correctly-sized positions all with pre-authorized Cardinal Rule exits. Next week's job is to manage the CRDF/UNCY exits, investigate the chain integrity failure, and stay disciplined until Phase B opens on 6/17.**

**Headline number to remember:** **15 wins / 1 loss / 16 trades / 93.75% / +$53,635 / +17.96% pool ROI / 184 days.**

— End of WEEK OF 2026-05-18 KAIZEN REVIEW —
